Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
Anas Younes, SVP, CMO and Global Head of Hematology, Oncology R and D at AstraZeneca, shared on LinkedIn:
”Every year, ASH25 is a moment to recognize the progress we’re making in hematology and celebrate the breakthroughs that help to transform care, from next-generation T-cell engagers to advances in cell therapy.
At AstraZeneca, we’re advancing a diverse range of innovations and expanding access to next-generation therapies that aim to deliver deeper, more durable responses while easing the daily burden of treatment for people living with blood cancer.
It’s great to continue these conversations throughout ASH and explore how these breakthroughs are potentially shaping a more hopeful future for blood cancer care.
Read my latest article to learn more.”
All from ASH25 featured in Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines
-
Dec 5, 2025, 03:45Ardeshir Khademi: A Clinical Lesson on Thrombophilia, Silent Infarcts, and Asking the Right Questions